Latest Advances in Lung Cancer Research

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Lung cancer cases in never-smokers are increasing, driven by air pollution and genetic mutations, particularly affecting women and younger patients.

Dana-Farber’s EQUAL study tests blood screening for EGFR mutations in Asian and Hispanic never-smokers at high lung cancer risk.

Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.

Dr. Suresh S. Ramalingam urges community oncologists to use molecular testing and expand lung-cancer screening — so more patients gain access to modern, personalized therapies.

Study shows 70 Gy radiation doses for lung cancer don’t increase pneumonitis risk and may improve survival compared to lower doses.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

A new study shows adding immunotherapy to chemotherapy before lung cancer surgery significantly improves five-year survival rates in patients.

Study of 1,143 lung cancer patients shows improved MET exon 14 mutation detection methods help select better targeted treatments.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

New AI model Sybil predicts future lung cancer risk from a single CT scan, offering hope for personalized screening, especially for Asian never-smokers.